Multiple Sclerosis Research Repository

1. “Impact of drug diversity on treatment effectiveness in relapsing-remitting multiple sclerosis (RRMS) in Germany between 2010 and 2018: real-world data from the German NeuroTransData multiple sclerosis registry”: Stefan Braune et al

-mean times to SPMS from diagnosis of RRMS remained unchanged at 17.8 years, corresponding with previous published data with a conversion time to SPMS on active treatment for 16.8 years

-the potential risk reduction for SPMS conversion on a broad spectrum of DMTs will have to be reevaluated in more detail as longer observation times on the new therapies become available